Umbralisib in Patients With CLL Intolerant to BTK or PI3Kδ Inhibitor Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients With CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
Blood 2020 Dec 01;[EPub Ahead of Print], AR Mato, N Ghosh, SJ Schuster, N Lamanna, JM Pagel, IW Flinn, J Barrientos, KR Rai, JA Reeves, BD Cheson, PM Barr, S Kambhampati, F Lansigan, JJ Pu, AP Skarbnik, LE Roeker, G Fonseca, A Sitlinger, IS Hamadeh, C Dorsey, N LaRatta, H Weissbrot, ET Luning Prak, PY Tsao, D Paskalis, P Sportelli, HP Miskin, MS Weiss, J Svoboda, DM BranderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.